

Faculty of Pharmacy¹ and Department of Obstetrics and Gynecology, Faculty of Medicine², University of Iceland, Reykjavik, Iceland

Sublingual delivery of 17 β -estradiol from cyclodextrin containing tablets

T. LOFTSSON¹, J. A. GUÐMUNDSSON², R. O. ÁRNADÓTTIR²,
H. FRÍÐRIKSDÓTTIR¹

Received December 6, 2002, accepted December 16, 2002

Prof. Dr. Thorsteinn Loftsson, Faculty of Pharmacy, University of Iceland, Hofsvallagata 53, IS-107 Reykjavik, Iceland
thorstlo@hi.is

Pharmazie 58: 358–359 (2003)

17 β -Estradiol is a rather lipophilic water-insoluble drug (log octanol/water partition coefficient (log K_{ow}) 2.58; solubility in water 0.1 mg/ml) [1, 2]. The drug is well absorbed from the gastrointestinal tract but due to first-pass effect its bioavailability after oral administration is only about 5%. It is possible to enhance the bioavailability of 17 β -estradiol by nasal, transdermal or sublingual administration [3–6]. Drug absorption from the oral cavity through the lipophilic mucosal membrane is a function of the surface area, permeability coefficient and the concentration of dissolved drug at the surface of the membrane [7]. The available surface area is relatively small or about 100–170 cm² and it is covered by an aqueous salivary film 0.07 to 0.10 mm thick. Thus the drug must be water-soluble to be able to permeate to the membrane surface and somewhat lipophilic to be able to permeate the lipophilic mucosal membrane. Cyclodextrins are relatively large hydrophilic molecules (MW ranging from about 1000 to over 2000) that form water-soluble complexes with many lipophilic drugs. They do not readily penetrate lipophilic biomembranes such as mucosal membranes. Studies have shown that cyclodextrins enhance drug delivery through lipophilic biological membranes by increasing the amount of dissolved drug molecules at the membrane

Table: Mean pharmacokinetic parameters of 17 β -estradiol following sublingual and nasal administration

Parameter	17 β -Estradiol (dose μ g)		
	Sublingual		Nasal ^a
	50	100	100
C_{max} (pmol/L)	400 $\pm$ 45	1084 $\pm$ 243	2560 $\pm$ 1020
t_{max} (h)	0.50	$\leq$ 0.25	0.17
$t_{1/2}$ (h) ^b	—	3.5	2.7

a From reference [4]

b The elimination half-life of exogenous 17 β -estradiol

surface. At the surface the drug molecules partition from the complex into the outermost layer of the membrane [8]. Thus cyclodextrins are able to increase the aqueous solubility of β -estradiol without reducing its ability to permeate the lipophilic mucosal membrane.

Previously, we have shown that 2-hydroxypropyl- β -cyclodextrin (HP β CD) forms a water-soluble complex with 17 β -estradiol and that the complex is able to deliver the lipophilic water-insoluble drug to the lipophilic membrane surface [3]. The purpose of the present study was to evaluate sublingual tablets containing 50 and 100 μ g of 17 β -estradiol in a HP β CD complex.

Sublingual tablets containing 17 β -estradiol/HP β CD complex, equivalent to 50 and 100 μ g 17 β -estradiol, were given to five postmenopausal women in an open crossover study and the estradiol plasma levels determined up to 12 h after administration (Fig.). The drug was rapidly absorbed with maximum plasma concentration (C_{max}) appearing within 15 to 30 min and terminal half-life ($t_{1/2}$) of about 3.5 h (Table). When compared to values obtained by Devissaguet et al. [4] it appears that 17 β -estradiol is more rapidly (somewhat shorter t_{max} and larger C_{max}) absorbed after nasal administration. However, nasal administration of drugs has been associated with large individual variations and pathological changes in the nasal mucosa [9]. The present study shows that systemic delivery of 17 β -estradiol from the buccal area is possible through cyclodextrin complexation of the drug. The sublingual drug delivery has many of the advantages of the nasal drug delivery but it is in general more reliable, less irritating and more convenient, which all leads to better patient compliance.

Experimental

One or two grams of 17 β -estradiol were dissolved, through heating in an autoclave to 120 °C for 20 min, in an aqueous 50% (w/v) HP β CD solution containing 0.25% (w/v) CMC [3]. The solution was then lyophilized in a Snijders lyophilizer (the Netherlands). Quantitative determinations of 17 β -estradiol in the complex powder were performed by HPLC. The lyophilized complex was mixed with lactose, croscopovidone, silica colloidalis and magnesium stearate. The tablets were directly compressed in a rotary tablet press (Stokes-Merrill, USA) using 6 mm punches with a target weight of 86.0 mg and disintegration time of less than 1 min. Five postmenopausal women (50 to 65 years old, 52 to 77 kg) were recruited for an open study. All the women were inpatients of the Department of Obstetrics and Gynecology, University Hospital, Reykjavik. The study was approved by the local ethical committee and the Ministry of Health. All the women volunteers signed an informed consent form. Before treatment, low endogenous 17 β -estradiol production was confirmed by measurement of FSH levels. The women received single doses of 50 or 100 μ g 17 β -estradiol in a buccal tablet. Blood samples were withdrawn over a period of 12 hours and the 17 β -estradiol concentration determined by time-resolved fluoroimmunoassay (DELFLIA) with reagents from Wallace, Finland. The detection limit was better than 50 pmol/l.




Fig.: Mean plasma concentrations of 17 β -estradiol after administration of sublingual tablets containing 100 μ g (○) and 50 μ g (●) of 17 β -estradiol. The error bars represent the SEM (n = 5)

References

- 1 Ekwall, P.; Sjoblom, L.: Acta Endocrinol. **4**, 179 (1950)
- 2 Wiedmann, T. S.; Kamel, L.: J. Pharm. Sci. **91**, 1743 (2002)
- 3 Friðriksdóttir, H.; Loftsson, T.; Guðmundsson, J. A.; Bjarnason, G. J.; Kjeld, M.; Thorsteinsson, T.: Pharmazie **51**, 39 (1996)
- 4 Devissaguet, J.-P.; Brion, N.; Lhote, O.; Deloffre, P.: Eur. J. Drug Metab. Pharmacokinet. **24**, 265 (1999)
- 5 Pines, A.; Averbuch, M.; Fisman, E. Z.; Rosano, G. M. C.: Maturitas **33**, 81 (1999)
- 6 Gompel, A.; Bergeron, C.; Jondet, M.; Dhont, M.; Van der Moeren, M. J.; Toth, K. S.; Panay, N.; Von Holst, T.: Maturitas **36**, 209 (2000)
- 7 Rathbone, M. J.; Drummond, B. K.; Tucker, I. G.: Adv. Drug Deliv. Rev. **13**, 1 (1994)
- 8 Loftsson, T.; Masson, M.: Int. J. Pharm. **225**, 15 (2001)
- 9 Arora, P.; Sharma, S.; Garg, S.: Drug Discov. Today **18**, 967 (2002)

Institute of Chemistry¹ and Department of Plant Physiology², Faculty of Natural Sciences, Comenius University, Bratislava, Slovakia

***Hypericum perforatum* L. and *Chamomilla recutita* (L.) Rausch. – accumulators of some toxic metals**

K. KRÁL'OVÁ, E. MASAROVÍČOVÁ

Received September 16, accepted November 22, 2002

RNDr. K. Králová, Institute of Chemistry, Comenius University, Mlynská dolina CH-2, SK-842 15 Bratislava, Slovak Republic

Pharmazie 58: 359–360 (2003)

The most important properties of medicinal plants used in phytotherapy are connected with the production of specific secondary metabolites exhibiting biological activity. Since medicinal plant species could sequester metal ions by some of these specific secondary metabolites, they are potentially useful in the process of phytoremediation.

Hypericum perforatum L. belongs to the class of cadmium hyperaccumulators. Cd(II) (toxic even at low concentrations) and Zn(II) (toxic only at high concentrations), can form somewhat less toxic organometallic complexes by binding with secondary metabolites. This finding was confirmed by an experiment with *H. perforatum* where the root system of six month old plants cultivated hydroponically in the presence of $12 \mu\text{mol dm}^{-3}$ Cd accumulated 7-times more Cd than the shoots. However, no significant changes were observed in production parameters (dry mass of roots and shoots) or in certain physiological characteristics (photosynthesis and mitochondrial respiration rates, photosynthetic electron transport chain between photosystem I and II, chlorophyll and carotenoid concentrations). On the other hand, root respiration rate significantly increased as a result of Cd treatment indicating a higher energy requirement for more intensive ion uptake mainly into the roots and thereafter also into the shoots [1, 2].

Grejtovský and Pirč [3] investigated the effect of Cd on two cultivars of *Chamomilla recutita* (L.) Rausch., diploid Novbona and tetraploid Lutea. They found that high Cd concentration in the soil (up to 30 mg kg^{-1}) caused stronger inhibition of growth parameters in diploid cv. Novbona. Addition of Cd to the soil resulted in higher Cd accumulation in all parts of the plants, however diploid Novbona exhibited higher Cd accumulation. We investigated the effects of Cd on 6 week old plants – *H. perforatum* and two cultivars of *Ch. recutita*, cv. Novbona and cv. Goral. The first cultivar of chamomile was more tolerant than the plants of *H. perforatum*. Comparing the two chamomile cultivars we found that at a Cd concentration of $120 \mu\text{mol dm}^{-3}$ cv. Novbona was more tolerant than cv. Goral. Even at a Cd concentration of $240 \mu\text{mol dm}^{-3}$ the growth parameters of the cv. Novbona plants were not influenced (except the root dry mass). Cv. Goral cultivated at $120 \mu\text{mol Cd dm}^{-3}$ accumulated $29.491 \text{ mg Cd g}^{-1}$ in the roots and $1.543 \text{ mg Cd g}^{-1}$ in the shoots whereas Cd accumulation in plant organs of cv. Novbona were approximately two times lower ($13.994 \text{ mg Cd g}^{-1}$ in the roots and $0.850 \text{ mg Cd g}^{-1}$ in the shoots). The non-significant negative effect of the studied metal on cv. Novbona could also be explained by lower Cd uptake by roots